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Abstract
b-site amyloid precursor protein (APP) cleaving enzyme 1 (BACE1) initiates the production of b-amyloid (Ab), the major
constituent of amyloid plaques in Alzheimer’s disease (AD). BACE1 is elevated ,2–3 fold in AD brain and is concentrated in
dystrophic neurites near plaques, suggesting BACE1 elevation is Ab2dependent. Previously, we showed that
phosphorylation of the translation initiation factor eIF2a de-represses translation of BACE1 mRNA following stress such
as energy deprivation. We hypothesized that stress induced by Ab might increase BACE1 levels by the same translational
mechanism involving eIF2a phosphorylation. To test this hypothesis, we used three different genetic strategies to
determine the effects of reducing eIF2a phosphorylation on Ab-dependent BACE1 elevation in vitro and in vivo: 1) a two-
vector adeno-associated virus (AAV) system to express constitutively active GADD34, the regulatory subunit of PP1c eIF2a
phosphatase; 2) a non-phosphorylatable eIF2a S51A knockin mutation; 3) a BACE1-YFP transgene lacking the BACE1 mRNA
59 untranslated region (UTR) required for eIF2a translational regulation. The first two strategies were used in primary
neurons and 5XFAD transgenic mice, while the third strategy was employed only in 5XFAD mice. Despite very effective
reduction of eIF2a phosphorylation in both primary neurons and 5XFAD brains, or elimination of eIF2a-mediated regulation
of BACE1-YFP mRNA translation in 5XFAD brains, Ab-dependent BACE1 elevation was not decreased. Additionally, robust
inhibition of eIF2a phosphorylation did not block Ab-dependent APP elevation in primary neurons, nor did it reduce
amyloid pathology in 5XFAD mice. We conclude that amyloid-associated BACE1 elevation is not caused by translational de-
repression via eIF2a phosphorylation, but instead appears to involve a post-translational mechanism. These definitive
genetic results exclude a role for eIF2a phosphorylation in Ab-dependent BACE1 and APP elevation. We suggest a vicious
pathogenic cycle wherein Ab42 toxicity induces peri-plaque BACE1 and APP accumulation in dystrophic neurites leading to
exacerbated Ab production and plaque progression.
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Introduction
The amyloid plaque, a hallmark of Alzheimer’s disease (AD)
pathology, is composed of a core of fibrillar 38–43 amino acid b-
amyloid Ab peptides [1,2]). Soluble oligomeric forms of Ab are
also thought to be present at high levels in the AD brain [3]. A vast
amount of evidence suggests that 42-amino acid Ab (Ab42) has a
crucial early role in the pathogenesis of AD [1,2]. Oligomeric
Ab42 has many toxic effects such as inhibition of long-term
potentiation in the hippocampus [4,5], alteration of synaptic
structure and synaptic transmission [6–11], and cytoskeletal
damage [12], among other effects in vitro and in vivo. Ab
peptides are generated by the sequential proteolytic processing
of the transmembrane protein, Amyloid Precursor Protein (APP)
by the b-secretase enzyme b-site APP Cleaving Enzyme 1
(BACE1), which cuts APP first, and the c-secretase complex,
which contains the intramembrane aspartic protease presenilin
(PS1, PS2) [13].
There is considerable genetic evidence suggesting that Ab42 is
the causative agent in Alzheimer’s disease. Mutations in APP, PS1
and its homolog, PS2, cause an early onset autosomal dominant
form of Familial Alzheimer’s Disease (FAD) [2]. Over 200
mutations in the genes for APP, PS1, and PS2 have been
identified that increase production of total Ab or Ab42, or increase
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Ab aggregation, and cause FAD. FAD can also be caused by
specific duplication of the APP gene locus [14,15], or by Trisomy
21/Downs syndrome [2]. The FAD mutations increase the rate of
secretase cleavage of APP resulting in greater Ab production [16].
For example, the Swedish mutation (K670N, M671L) at the
BACE1 cleavage site in APP makes APP a better BACE1
substrate, and thus increases BACE1 cleavage and raises total Ab
generation to cause FAD [17]. This implies that increased BACE1
activity might result in AD. Moreover, except for age of onset, the
phenotypes of FAD and sporadic AD are highly similar, strongly
suggesting that Ab has a critical early role in the more common
sporadic form of AD. Recently, a mutation in APP near the
BACE1 cleavage site (A673T) was identified that protects against
AD by reducing BACE1 cleavage of APP and Ab production [18].
These results taken together suggest that therapeutic reduction of
the activities of the secretases, especially BACE1, should lower Ab
levels, which might be beneficial for AD.
It is consistently observed that levels of BACE1 protein and
activity are elevated in the brains of AD patients [19–23] and APP
transgenic (Tg) mice [22,24–26], suggesting that increased BACE1
could have a role in the development and/or progression of AD by
exacerbating Ab generation. While the mechanism of BACE1
elevation in AD and APP Tg brains is not fully understood, recent
data indicate that BACE1 levels are upregulated during stresses
associated with AD risk such as energy deprivation [22,27],
hypoxia and stroke [28–30], oxidative stress [31] and traumatic
brain injury [32,33]. Several molecular pathways have been
proposed to mediate the BACE1 elevation, such as caspase-3-
induced cleavage of the trafficking adaptor protein GGA3 leading
to impaired lysosomal degradation of BACE1 [34,35], Cdk5
phosphorylation of transcription factor Stat3 [36], altered levels of
microRNAs [37–41], increased transcription factor HIF1a activity
[29], and elevated BACE1 mRNA translation via phosphorylation
of the translation initiation factor eIF2a [22].
In the brains of APP Tg mice and AD patients, high
concentrations of BACE1 protein accumulate in swollen dystro-
phic neurites in very close proximity to amyloid plaques
[22,24,26], suggesting that Ab itself is responsible for raising
BACE1 levels [42]. However, the complexity of the regulation of
BACE1 levels in neurons has made it difficult to discern the
molecular and cellular mechanism(s) involved in Ab-dependent
BACE1 elevation. Our previous work using primary neuron
cultures indicates that Ab42 oligomers directly elevate BACE1
levels through a post-transcriptional mechanism independent of
caspase-3 and Cdk5 activity [25]. Since these molecules did not
seem to play a key role in Ab42-induced BACE1 elevation, we
focused on the eIF2a phosphorylation pathway, which we have
previously shown increases BACE1 levels via enhanced translation
of BACE1 mRNA following energy inhibition [22]. In primary
neurons, compounds that increase eIF2a phosphorylation, such as
the PP1c phosphatase inhibitor salubrinal, also increase BACE1
levels and Ab generation. In BACE1 overexpressing HEK cells,
genetic reduction of eIF2a phosphorylation prevents the BACE1
increase associated with energy inhibition, further verifying this
mechanism. The positive correlation of levels of BACE1,
phosphorylated eIF2a, and amyloid load in human brain along
with the significant increase of BACE1 and phospho-eIF2a levels
in AD brains compared to non-demented controls [22] suggests
the eIF2a phosphorylation pathway might be relevant to AD
pathogenesis. Lastly, the increase of both BACE1 and phospho-
eIF2a levels in the 5XFAD transgenic mouse model of aggressive
amyloid pathology [22] indicates that this animal model could be
useful for studying the role of eIF2a phosphorylation in BACE1
elevation and amyloidogenesis in AD.
eIF2a is phosphorylated in response to certain cell stressors such
as viral infection, hypoxia, low nutrients and accumulation of
unfolded proteins in the ER. Phosphorylation of eIF2a reduces
global translation of transcripts, but increases translation of specific
stress-response mRNAs that encode proteins that limit damage
and assist the cell during stress recovery. The eIF2 complex
functions by binding GTP and initiator tRNA, then scanning the
mRNA until it reaches a start codon where it hydrolyzes GTP and
dissociates while the ribosome continues translation. Normally,
eIF2B is the guanine nucleotide exchange factor for eIF2, but
when the a subunit of eIF2 is phosphorylated at serine 51 (S51),
eIF2 binds tightly to eIF2B thus inhibiting its guanine nucleotide
exchange activity and eIF2 is unable to load GTP and initiate
translation. As a result of eIF2a phosphorylation, certain mRNA
transcripts with long 59 untranslated regions (UTRs) that contain
short upstream open reading frames (uORFs) are translated with
increased efficiency because ribosomes have an increased proba-
bility of scanning through the uORFs to re-initiate translation at
the true start codon [43,44]. Similarly, the BACE1 transcript has a
long, GC-rich 59 UTR that contains three uORFs that represses
translational efficiency under basal conditions [45–48]. eIF2a
phosphorylation that is induced by energy deprivation causes de-
repression of BACE1 mRNA translation, thus resulting in
increased BACE1 protein levels [22].
Here, we employed three different genetic strategies to
determine the effects of reduced eIF2a phosphorylation on Ab-
dependent BACE1 elevation in vitro and in vivo: 1) a two-vector
adeno-associated virus (AAV) system to express constitutively
active GADD34, a regulatory subunit of the PP1c eIF2a
phosphatase; 2) a non-phosphorylatable eIF2a S51A knockin
mutation [49]; 3) a BACE1-YFP transgene lacking the BACE1
mRNA 59 UTR that is required for translational regulation by
phosphorylated eIF2a. The first two strategies were used in
primary neuron cultures and 5XFAD transgenic mouse brains,
while the third strategy was employed only in 5XFAD transgenic
mice. We report that despite very effective reduction of
phosphorylated eIF2a levels in both primary neuron cultures
and 5XFAD brains, or elimination of phosphorylated eIF2a
mediated regulation of BACE1-YFP mRNA translation in
5XFAD brains, Ab-dependent BACE1 elevation could not be
decreased. We conclude that the amyloid-associated increase in
BACE1 level is not caused by translational de-repression via eIF2a




GADD34 constitutive active N-terminal truncation and
GADD34 control C-terminal truncation constructs were a
generous gift of Dr. David Ron. GADD34 CA and GADD34
control cDNAs were expressed from a recombinant adeno-
associated virus (AAV)-based two-vector system. Each cDNA
was cloned into an AAV ‘‘responder vector’’ consisting of a tTA-
regulated tet-operator-CMV (tetO-CMV) bidirectional promoter
driving coexpression of GADD34 CA and eGFP or GADD34
control and eGFP. Expression from the responder vector is
activated only in the presence to the tetracycline transactivator
protein (tTA), which is expressed from an ‘‘activator vector’’ under
the control of the forebrain pyramidal neuron-specific calmodulin
kinase II (CaMKII) promoter [50].
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Mice
5XFAD mice were generated as previously described [51]. The
5XFAD line was maintained by crossing transgene positive males
with B6/SJL F1 hybrid females from Jackson Laboratories. The
eIF2a S51A mice were generated as described [49], and
maintained by crossing S/A heterozygous mice to wild type mice.
BACE1-YFP were generated as described [52]. Briefly, eYFP was
fused to the coding region of human BACE1, and cloned into the
PMM400 tetO expression vector (gift of M. Mayford, The Scripps
Institute, La Jolla, CA). This construct was used to make tetO
promoter BACE1-YFP transgenic mouse lines, which were then
crossed to transgenic mice expressing the tet transactivator (tTA)
from the forebrain pyramidal neuron-specific CaMKII promoter
(gift of M. Mayford) generating CaMKII:BACE1-YFP bigenic
mice that express BACE1-YFP in forebrain neurons (referred to as
BACE1-YFP mice). These bigenic females were crossed to
5XFAD males to generate 5XFAD;BACE1-YFP and non-5XFAD
BACE1-YFP littermates. For all experiments, cohorts consisted of
approximately 50% male and 50% female mice for each genotype,
except for all BACE1-YFP and 5XFAD;BACE1-YFP mice were
female. In no experiment did we observe a difference in BACE1
level or phospho:total eIF2a ratios between the sexes, so analyses
of males and females were combined. All mice were genotyped by
PCR amplification of tail clip DNA. Mice were sacrificed by
carbon dioxide inhalation or by a lethal dose of ketamine/
xylazine, followed by perfusion with ice cold 1xPBS containing
protease and phosphatase inhibitors. One hemibrain was either
snap-frozen whole in liquid nitrogen, or dissected into hippocam-
pus and cortex which were snap-frozen separately. Snap frozen
hemibrains, cortices or hippocampi were homogenized in 1xPBS
with 1% Triton X-100 supplemented with protease inhbitors
(Calbiochem) and Halt Phosphatase Inhibitor Cocktail (Thermo
Scientific). Protein concentration was quantified using BCA Assay
(Pierce). The other hemibrain was drop fixed in 4% paraformal-
dehyde in PBS for 16–20 hrs, then transferred to 20% w/v sucrose
in 1xPBS for 24 hours, then stored in 30% w/v sucrose in 1xPBS
with azide. All animal work was done with the approval of the
Northwestern University IACUC, assurance number A3283-01.
AAV injection
Serotype 1 AAV was prepared by VectorBioLabs (Philadelphia,
PA). Genomic titer was determined by quantitative PCR. 5XFAD
transgene positive males were crossed to SJL/B6 hybrid females in
timed matings to generate transgene negative and positive
littermates. On P0, each pup in a litter was cryoanesthatized
and injected with 2 ml containing 6.661010 viral genomes of
GADD34 control-AAV or GADD34 CA-AAV and 6.961010 viral
genomes of CamKII-tTA activator vector into each hemisphere,
using a 10 ml Hamilton syringe, as described in [53]. Pups were
returned to the mother and aged to 1, 3, or 6 months.
Primary neurons, AAV and Ab42
Timed matings between C57/B6 pairs or eIF2a S/A hetero-
zygous pairs were set up for two nights. Cortical neurons were
isolated from day 15.5–16.5 mouse embryos via dissociation at
37uC in 0.25% trypsin. For immunoblotting, brains were plated at
the density of 750,000 cells per well in 12 well plates previously
coated with 1 mg/ml poly-L-lysine (Sigma) in borate buffer.
Neurons were plated in neurobasal media supplemented with 2%
B-27, 500 mM glutamine, 10% horse serum and 2.5 mM
glutamate. After 2–3 hours, this was replaced with growth media
(neurobasal media with 2% B-27 and 500 mM glutamine). All cell
culture reagents were from Invitrogen. For AAV infection, 16107
activator viral genomes and 16107 responder GADD34 control or
GADD34 CA viral genomes were added to each well when the
plating media was removed and replaced with growth media.
AAV for primary neuron experiments was prepared by poly-
ethylenimine transfections of HEK cells with activator or
responder GADD34 vectors, and helper plasmids containing the
genes required for viral packaging. The helper plasmids used
(pDP1, pDP2) [54] generated combined serotype of 1 and 2,
which efficiently transduces neurons, and can be purified on a
heparin column [55]. Briefly, HEK293T/17 cells (ATCC) were
plated in T225 flasks and transfected by linear polyethylenimine
(PEI) [56,57] with equal molar amount of either responder
GADD34 cont, GADD34 CA or activator, and pDP1 and pDP2.
The cells were collected 72 hours after transfection by scraping.
Cells were lysed with freeze/thaw cycles followed by Benzonase
and pelleted. The virus containing supernatant was filtered on
0.45 mM Acrodisc syringe filter and loaded onto a heparin column
(GE Healthcare). Virus was washed with 1 mM MgCl and
2.5 mM KCl in 1xPBS (PBS-MK) and eluted in PBS-MK with
0.5 M NaCl. The eluted virus was concentrated in Amicon Ultra
cut off column (Millipore), washed thoroughly with PBS-MK three
times then eluted in 200 ml PBS. Virus titer (genomic particles per
ml) was determined by quantitative real-time PCR using RT2
Real-Time SYBR Green/Fluorescein PCR master mix, according
to the manufacturer (SuperArray Bioscience).
After 6–8 days in vitro following AAV infection, neurons were
exposed to 10 mM oligomeric Ab42 for 24 or 30 hours or 1 mM
Ab42 for 5 days. Ab42 oligomers were prepared as described in
[58]. Briefly, lyophilized recombinant Ab42 peptide (rPeptide) was
HFIP treated, dried down, then resuspended to 5 mM in dry
DMSO and brought to 100 mM in cold, 4 mM HEPES pH 8,
incubated on ice at 4uC for 24 hours to generate oligomers [59].
For control cultures, DMSO alone was added to 4 mM HEPES
pH 8 and incubated as described. All treatment conditions were
done in triplicate. Neurons were lysed on ice in RIPA buffer
(150 mM NaCl, 1% IGEPAL CA-630, 0.5% sodium deoxycho-
late, 0.1% SDS, 50 mM Tris pH 8, 1 mM PMSF) with protease
inhibitors (Calbiochem) and Halt Phosphatase Inhibitor Cocktail
(Thermo Scientific), spun down 10 minutes at 10,000 RPM at
4uC, and protein in the supernatant quantified by BCA assay
(Pierce).
Immunoblotting
15 or 20 mg of brain homogenate, or 5–10 mg primary neuron
lysate were separated on Invitrogen’s 4–12% Bis-Tris NuPage
Mini Gels. Protein was transferred to 0.45 mm PVDF membrane,
and after transfer stained with 0.1% Ponceau in 5% w/v acetic
acid, and scanned. The membrane was rinsed and probed with
anti-BACE1 antibody (3D5; 1:1000) [26], anti-phospho-eIF2a
(Epitomics, clone E90, 1:2000 or Cell signaling #3597, 1:2000),
anti-eIF2a (Cell Signaling #9722, 1:2000), anti-APP/Ab (clone
6E10, Covance, 1:5000, for human APP/Ab, or clone 22C11,
Millipore, 1:2000, for mouse APP), anti-GFP (Clontech, Living
Colors #632375), anti-bIII-tubulin (TuJ1, gift of Dr. Lester
Binder, 1:10,000) anti-b-actin (Sigma clone AC-15, #A5441-
1:30,000), anti-caspase 3 (Cell Signaling #9662-1:1000), followed
by washing and 1 hour incubation with secondary HRP-
conjugated anti-mouse or anti-rabbit secondary antibody (Jackson
Immunologicals, Vector Laboratories 1:10,000). Blots were
visualized using Amersham’s ECL+ chemiluminescent substrate,
or Luminata Crescendo (Millipore), and signals were quantified
using a Kodak Image Station 4000 R. Signals were normalized to
tubulin or actin signal, or ponceau staining intensity as indicated in
figure legends. For analysis of the mouse brain homogenates, gels
were cut into horizontal strips and stacked so all samples for a
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given protein were transferred onto a single piece of PVDF
membrane. Putting all samples (up to 106) on one membrane
eliminated the need to account for variation in transfer, antibody
incubation and ECL application that can occur between blots. For
neurons, triplicates of each culture condition were averaged and
comparison to control was done using student’s two-tailed t-test
using InStat software (GraphPad Software, Inc., San Diego, CA).
Ab42 ELISA
Human Ab42 levels in the 5XFAD AAV-injected cortices were
measured using the WAKO Human bAmyloid (1–42) Kit as
follows. 7.5 mg/ml brain homogenates were extracted in 5 M
guanidine hydrochloride overnight on a rocker, then diluted 1:50
in PBS with protease inhibitors. All samples were then diluted
1:100 into Standard Diluent and ELISA was performed according
to manufacturer’s instructions.
Immunofluorescence and microscopy
Paraformaldehyde fixed brains stored in 30% sucrose in PBS
were cut into 30 mm coronal or saggital sections on a freezing
sliding microtome and collected in PBS. Sections were stained
with Thiazine Red (2 mg/ml diluted 1:60,000) or Thioflavin S
(1 mg/ml diluted 1:5000) for amyloid fibrils, BACE1 (D10E5, Cell
Signaling, 1:500 or Eptomics EPR3956 1:250), GADD34 (Protein
Tech Group, Chicago 1:1000). GFP and YFP fluorescence signals
were imaged directly. Donkey anti-rabbit or anti-mouse conjugat-
ed to Alexa 568 or 647 secondary antibody (Molecular Probes)
was used at the same concentrations as primary being detected.
DAPI (Molecular Probes) was used at 300 nM for imaging nuclei.
Coverslips were mounted using Prolong Gold (Molecular Probes),
Conventional images were collected using a Keyence BZ9000
microscope (Tokyo, Japan), using 10x or 20x objectives. The
‘‘merge’’ function was used to generate hemibrain and hippocam-
pus images. Confocal images were collected on Nikon A1
microscope using a 60x oil immersion objective lens and NIS
Elements software (Northwestern University’s Cell Imaging
Facility).
Results
Overexpression of constitutively active GADD34 blocks
eIF2a phosphorylation but does not prevent Ab42-
induced BACE1 elevation in cultured mouse cortical
primary neurons
We previously reported that energy deprivation induces
phosphorylation of the translation initiation factor eIF2a and that
this in turn increases protein synthesis of the b-secretase enzyme,
BACE1, in primary cultured neurons and in the brain [22].
Additionally, we found that levels of phosphorylated eIF2a (p-
eIF2a) positively correlate with BACE1 levels and amyloid loads in
human AD and APP transgenic mouse brains [22]. Furthermore,
we observed that BACE1 levels increase in dystrophic presynaptic
terminals that are in close proximity to amyloid plaques in AD and
APP transgenic brains [24,26] and that fibrillar and oligomeric
Ab42 cause BACE1 levels to increase ,1.5–3-fold in primary
neuron cultures [25]. Together, these results suggested the
possibility that Ab might induce eIF2a phosphorylation and cause
an increase in BACE1 level via a translational mechanism similar
to that of energy deprivation. To investigate this hypothesis, we
established an in vitro culture system of Ab42-induced BACE1
elevation in mouse primary cortical neurons (Fig. 1). Synthetic
Ab42 oligomers and fibrils [58] robustly elevate BACE1 levels in
primary neuron cultures within 24 hrs, although Ab42 oligomers
appear more potent [25]. Therefore, we treated E15.5 mouse
mixed cortical primary neuron cultures with 10 mM Ab42
oligomers or vehicle for 24 and 48 hrs and then performed
immunoblot analyses for levels of BACE1, p-eIF2a, and total
eIF2a (Fig. 1). As expected, Ab42 oligomers caused significant
increases in BACE1 levels in both 24- and 48-hr treated primary
neurons. Moreover, the p-eIF2a/total eIF2a ratio was also
significantly elevated by Ab42 oligomer compared to vehicle
treatment. APP levels are also robustly increased by Ab42,
suggesting the intriguing possibility that Ab42 induces elevation of
both BACE1 and APP to initiate a pathogenic feed-forward cycle
of accelerated Ab42 generation. These results validated our
primary neuron culture system for investigating the molecular
mechanism of Ab-induced BACE1 elevation and the potential
involvement of eIF2a phosphorylation in this process.
To determine whether eIF2a phosphorylation mediates the Ab-
induced increase of BACE1 level in primary neurons in vitro, we
undertook two genetic approaches to reduce p-eIF2a levels:
Growth Arrest and DNA Damage protein 34 (GADD34)-
mediated eIF2a de-phosphorylation [60] and the S51A targeted
eIF2a mutant allele that prevents eIF2a phosphorylation [49]. In
the first approach, we employed GADD34, a regulatory subunit of
protein phosphatase 1c (PP1c) responsible for de-phosphorylating
eIF2a at serine 51 following recovery from certain types of
physiological stress [61]. The carboxy-terminal region of
GADD34 activates PP1c, but normally this interaction is inhibited
by the amino-terminal domain of GADD34. However, a
GADD34 construct that lacks the inhibitory amino-terminal
domain constitutively de-phosphorylates eIF2a [60]. Overexpres-
sion of this constitutively active GADD34 construct (GADD34
CA) greatly reduces levels of p-eIF2a, while a GADD34 lacking
the carboxy-terminal activation domain (GADD34 control) has no
effect on eIF2a phosphorylation and is frequently used as a
negative control [60,61].
We generated adeno-associated virus (AAV) ‘‘responder’’
vectors that co-express GADD34 CA or GADD34 control
(GADD34 CA-AAV and GADD34 control-AAV, respectively)
along with green fluorescent protein (GFP) under the control of a
bi-directional tetO-CMV fusion promoter [50] (Fig. 2A). The
transcription of GADD34 CA and GADD34 control is activated
in the presence of a second ‘‘activator’’ AAV vector that expresses
the tetracycline transactivator (tTA) under the control on the
forebrain excitatory neuron-specific calmodulin kinase II promoter
(CaMKII tTA-AAV). Addition of the tetracycline analog, doxy-
cycline, inactivates GADD34 CA or GADD34 control transcrip-
tion. However, because we did not use doxycycline, GADD34 CA
or GADD34 control transcription was constitutive in these
experiments. GADD34 CA-AAV or GADD34 control-AAV was
added together with CaMKII tTA-AAV to E15.5 mouse mixed
cortical primary neurons. The media was changed after 48 hours
and the neurons were harvested at 7 days in vitro and subjected to
immunoblot analysis (Fig. 2B). Notably, eIF2a phosphorylation
was dramatically decreased in the primary neurons transduced
with GADD34 CA AAV compared to GADD34 control-AAV,
which caused a modest increase in p-eIF2a level (Fig. 2C).
Transduction with either AAV vector resulted in only a small
increase in pro-apoptotic cleaved caspase 3 (17 kDa) fragment.
These results demonstrated that GADD34 CA AAV could
effectively transduce primary neurons with minimal toxicity and
cause a significant reduction in p-eIF2a level.
Next, we sought to determine whether GADD34 CA AAV-
mediated reduction of eIF2a phosphorylation could inhibit the
Ab42-induced BACE1 increase in primary neurons. Primary
neuron cultures were transduced with GADD34 CA-AAV or
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GADD34 control-AAV for 48 hrs as described above, then 7 days
later were treated with 10 mM Ab42 oligomers for 30 hrs. Ab42
oligomers were prepared from HFIP lyophilized recombinant
Ab42, as described previously [43,51]. Following Ab42 treatment,
primary neurons were lysed in RIPA buffer and subjected to
immunoblot analysis (Fig. 3). As expected, in the absence of either
AAV vector, Ab42 oligomer treatment caused a ,2-fold increase
of both BACE1 level and the ratio of phosphorylated to total (p:t)
eIF2a in primary neurons. Interestingly, transduction with
GADD34 control-AAV alone significantly elevated BACE1 level
and p:t eIF2a ratio. Likewise, GADD34 CA-AAV alone also
increased BACE1 level but completely abolished eIF2a phosphor-
ylation, indicating an eIF2a phosphorylation independent mech-
anism of Ab42-induced BACE1 elevation. Combined Ab42
treatment plus GADD34 control-AAV transduction caused ,3-
fold and ,2.5-fold increases in BACE1 level and p:t eIF2a ratio,
respectively, even higher than Ab42 oligomers alone, suggesting
an additive Ab42-AAV effect. Combined Ab42 treatment plus
GADD34 CA-AAV transduction of primary neurons resulted in a
,2.5 fold increase in BACE1 level but nearly completely
abrogated eIF2a phosphorylation. Interestingly, APP levels were
robustly increased by Ab42 and both AAV vectors, either in single
treatment or in combination with Ab42. It is notable that the
combination of Ab42 plus either AAV vector most potently
elevated BACE1 and APP levels. Taken together, these results
suggest that Ab42 is capable of elevating BACE1 and APP levels
via a mechanism that does not depend upon phosphorylation of
eIF2a, at least in primary neurons.
The eIF2a S51A knockin mutation blocks eIF2a
phosphorylation but does not prevent Ab42-induced
BACE1 elevation in cultured mouse cortical primary
neurons
To confirm our results that reducing the phosphorylation of
eIF2a using GADD34 CA-AAV does not prevent Ab42-induced
BACE1 elevation in primary neurons, we turned to a different
genetic model to block eIF2a phosphorylation: eIF2a S51A
knockin mouse primary neurons. S51A targeted replacement mice
have an alanine in place of the serine 51 that becomes
phosphorylated under certain conditions of physiological stress;
consequently, eIF2a cannot be phosphorylated in these animals
[49]. Homozygous (A/A) eIF2a S51A knockin mice die soon after
birth as a result of hypoglycemia, but heterozyotes (S/A) are viable
and fertile [49]. Thus, we were able to obtain primary mixed
cortical neuron cultures from E15.5 embryos of S/A6S/A mouse
crosses. Primary neurons were harvested from the cortex of each
embryo individually to obtain pure A/A and S/A cultures. After
7DIV, primary neurons were treated with 10 mM oligomeric
Ab42 for 30 hrs, then were harvested and subjected to immuno-
blot analysis (Fig. 4). As with wild-type primary neurons, Ab42
oligomer treatment caused BACE1 level and p:t eIF2a ratio to
increase significantly in S/A neuron cultures, compared to vehicle
Figure 1. BACE1, APP, and phosphorylated eIF2a increase in response to Ab42 oligomer treatment of primary neurons.Mixed cortical
primary neurons were isolated from e15.5 mouse embryos, and after 7 days in culture, exposed to 10 mM oligomeric Ab42 for 24 and 48 hrs. Cells
were lysed in RIPA buffer and 10 mg/lane of protein were subjected to immunoblot analysis for APP, BACE1, phosphorylated (p)-eIF2a, total eIF2a,
and b-actin as a loading control. (–) and (+) are negative and positive controls for eIF2a phosphorylation (control and UV treated HEK cell lysates, Cell
Signaling). APP and BACE1 immunosignal intensities were normalized to those of b-actin. Phosphorylated and total eIF2a immunosignal intensities
were measured and phosphorylated:total eIF2a ratio calculated. APP and BACE1 levels and phosphorylated:total eIF2a ratio (all measures displayed
as percentage of vehicle control) are all significantly elevated by Ab42 oligomer treatment at both time points. Bars represent SEM, n = 3 samples per
condition, asterisks (*) indicate significant changes compared to respective vehicle, p,0.05*, p,0.01**, p,0.001***.
doi:10.1371/journal.pone.0101643.g001
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treated S/A cultures. Importantly, A/A primary neurons showed a
similar Ab42-induced increase in BACE1 level as S/A neurons
even though eIF2a phosphorylation was completely abrogated in
Ab42 treated A/A neurons. Once again, APP levels were robustly
increased by Ab42 treatment in both S/A and A/A neuron
cultures. Therefore, as with GADD34 CA-AAV transduced
primary neurons treated with Ab42, our results with A/A neurons
indicate that a mechanism other than eIF2a phosphorylation is
responsible for Ab42-induced BACE1 and APP elevation in
primary neurons.
Overexpression of constitutively active GADD34 inhibits
eIF2a phosphorylation but does not reduce BACE1
elevation in 5XFAD transgenic mouse brain
Although our in vitro experiments definitively showed that
eIF2a phosphorylation is not required for Ab-induced BACE1
elevation, mature neurons in the brain are clearly different than
cultured primary neurons in many respects and therefore might
need phosphorylated eIF2a to increase BACE1 levels in response
to amyloid plaques. To test this possibility, we used the two genetic
approaches we employed before, GADD34 CA-AAV transduction
and eIF2a S51A knockin mice, to reduce p-eIF2a levels in
cerebral neurons of the 5XFAD transgenic (Tg) mouse model of
amyloidosis [51]. This mouse line expresses two linked transgenes,
both driven by the Thy1 promoter: 1) the 695 amino acid isoform
of human APP with three famililal Alzheimer’s disease (FAD)
linked mutations called Swedish (K670N, M671L) [62], Florida
(I716V) [63] and London (V717I) [64]; 2) human PS1 with the
two FAD mutations M146L and L286V [65]. These five
mutations result in massive overproduction of Ab42, intraneuronal
Ab42 accumulation, plaque deposition at 2 months, memory
impairment at 4–5 months, and neuron loss starting at 6 months
[51,66]. 5XFAD mice rapidly develop florid amyloid pathology.
Additionally, BACE1 levels are globally increased ,1.5-fold in
5XFAD brain, with the vast majority of this BACE1 elevation
being concentrated in dystrophic neurites that are in close
proximity to amyloid plaques (Fig. 5; [24,26]). Moreover, previous
work had indicated that both phosphorylated and total eIF2a
levels were elevated in 5XFAD brain at 6 months, leading to a
small but significant increase in the p:t eIF2a ratio [22]. Thus, we
reasoned that the 5XFAD mouse is an appropriate model for
investigating the potential role of eIF2a phosphorylation in
BACE1 elevation near amyloid plaques.
First, we transduced GADD34 CA-AAV into the brains of
5XFAD mice using the somatic brain transgenesis technique,
which results in expression of the AAV vector transgene
throughout the brain for the life of the mouse [53,67,68]. High-
titer AAVs were bilaterally injected into the lateral ventricles of
post-natal day 0 (P0) pups within hours of birth. In a pilot
experiment, immunoblot analysis of homogenates from control
AAV-injected hemibrains harvested at 1 and 3 months of age
showed that AAV transduction did not elevate BACE1 or p-eIF2a
levels in the brain (data not shown), in contrast to cultured primary
neurons, indicating that AAV on its own does not appear to
perturb the expression, regulation, or metabolism of these proteins
in vivo.
Figure 2. AAV vectors efficiently transduce primary neurons
and block eIF2a phosphorylation with minimal toxicity. (A) A
two-vector adeno-associated virus (AAV) system was used to decrease
eIF2a phosphorylation specifically in excitatory forebrain neurons. The
‘‘activator’’ vector (CaMKII tTA-AAV) expresses the tetracycline transac-
tivator (tTA) protein from a calmodulin kinase II (CaMKII) promoter,
while the ‘‘responder’’ vector (GADD34 CA-AAV or GADD 34 cont–AAV)
expresses GFP and either GADD34 constitutive active (CA) or GADD34
control (cont) from a bi-directional tetracycline operator-CMV promoter
(tetO-CMV). All expressed transgenes contain a woodchuck post-
trascriptional regulatory element (WRE) to enhance expression. ITR =
inverted terminal repeat sequences. (B) Mixed cortical primary neurons
were isolated from e15.5 mouse embryos and infected with 16107 viral
genomes of CaMKII tTA-AAV and 16107 viral genomes of GADD34 CA-
AAV or GADD 34 cont–AAV per well of a 12 well plate on the day of
isolation. No virus was added to other wells as a negative control. Media
was changed 48 hours later. After 8 days in culture, neurons were lysed
for immunoblot analysis for total eIF2a, phosphorylated (p)-eIF2a, GFP,
caspase 3 (full length and activated cleaved 17 kDa fragment), and b-
actin as a loading control. (+) are HEK293 cells treated 30 minutes with
1 mM thapsigargin as a positive control for eIF2a phosphorylation, while
(–) are untreated HEK293 cells as a negative control. Note that AAV
transduction does not cause toxicity as indicated by minimal cleaved
caspase 3 fragment. (C) Phosphorylated and total eIF2a immunosignal
intensities were measured from the blot in (B) and phosphorylated:total
eIF2a ratio (phospho/total eIF2a) was calculated and displayed as
percentage of no virus control. Primary neurons transduced with
GADD34 CA-AAV had dramatically less eIF2a phosphorylation than
neurons transduced with GADD34 cont-AAV or no virus, as demon-
strated by phospho/total eIF2a ratio. Note that GADD34 cont-AAV
transduction caused a significant elevation of phospho/total eIF2a ratio
compared to no virus control. Bars represent SEM, n = 3 samples per
condition, p,0.01**.
doi:10.1371/journal.pone.0101643.g002
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Next, we injected GADD34 CA-AAV or GADD34 control-
AAV, together with the activator CamKII-tTA AAV, into the
ventricles of P0 5XFAD and non-Tg pups, allowed mice to age to
6 months, and then harvested cortices and hippocampi for
biochemical and histological analyses of BACE1, p-eIF2a, and
Ab42. Importantly, GADD34 CA-AAV and GADD34 control-
AAV vectors were able to transduce and express at similar levels in
the brain as indicated by GFP fluorescence in brain sections
(Fig. 6A) and GFP immunoblot analysis of brain homogenates
(data not shown). Brain sections immunostained with an antibody
against GADD34 showed that GADD34 CA co-localized well
with GFP (Fig. 6B), suggesting that GFP fluorescence is a good
proxy for GADD34 transgene expression. Both AAVs displayed a
neuronal expression pattern, as expected for the CaMKII
promoter, with highest levels in the hippocampus followed by
the cortex. Immunoblot analysis of homogenates from 6 month
old hippocampi and cortices showed no difference in BACE1 or p-
eIF2a level in hippocampus or cortex between uninjected and
GADD34 control-AAV injected mice of either non-Tg or 5XFAD
genotypes (Fig. 6C, D). This results confirms our previous pilot
experiment showing that AAV on its own does not affect BACE1
or p-eIF2a levels in the brain, in contrast to AAV transduction of
primary neurons in culture (Figs. 2, 3). As expected, BACE1 levels
were significantly increased in 5XFAD compared to non-Tg
brains, irrespective of AAV injection (Fig. 6C, D). However, p:t
eIF2a ratio was not elevated by the presence of the 5XFAD
transgene, contrary to our previous observation [22]. The reason
for the absence of an increased p:t eIF2a ratio in 5XFAD brain is
unclear and is currently under investigation.
We next sought to determine the effects of GADD34 CA-AAV
on BACE1 and p-eIF2a levels in brains of 6 month old 5XFAD
mice (Fig. 7). Immunoblot analysis for p-eIF2a revealed that
GADD34 CA-AAV injection produced a very effective reduction
(,85–90%) of the p:t eIF2a ratio in the hippocampus and cortex
of both non-Tg and 5XFAD mice, compared to GADD34
control-AAV injection (Fig. 7A, B). Importantly, immunoblots
showed that no significant difference in BACE1 level was observed
between 5XFAD brains injected with GADD34 CA-AAV
compared to GADD34 control-AAV, despite robust reduction of
eIF2a phosphorylation for the former. Additionally, immunolabel-
ing of 5XFAD brain sections with an anti-BACE1 antibody
revealed no difference in the level of BACE1 immunostaining
between GADD34 CA-AAV and GADD34 control-AAV injec-
tion (Fig. 7D). Moreover, Ab42 level by ELISA (Fig. 7C) and
amyloid plaque signal by thiazine red staining (Fig. 7D) of 5XFAD
brain homogenates and sections, respectively, also showed no
significant changes in response to GADD34 CA-AAV compared
to GADD34 control-AAV injection. Taken together, these results
demonstrate that amyloid-associated BACE1 elevation in the
brain is not dependent upon the phosphorylation of eIF2a.
Figure 3. In primary neurons, GADD34 CA-AAV mediated reduction of eIF2a phosphorylation does not inhibit BACE1 and APP
elevation in response to Ab42 oligomer treatment.Mixed cortical primary neurons were isolated from e15.5 mouse embryos and infected with
16107 viral genomes CaMKII tTA-AAV and 16107 viral genomes of GADD34 CA-AAV or GADD 34 cont–AAV per well of a 12 well plate on the day of
isolation. No virus was added to other wells as a negative control. Media was changed 48 hours later. After 7 days in culture, neurons were treated
with vehicle or 10 mM Ab42 oligomers generated as described [58,59], lysed 30 hours later, and 10 mg/lane of protein were subjected to immunoblot
analysis for APP, BACE1, total eIF2a, phosphorylated (p)-eIF2a, and b-actin as a loading control. APP and BACE1 immunosignal intensities were
normalized to those of b-actin. Phosphorylated and total eIF2a immunosignal intensities were measured and phosphorylated:total eIF2a (phospho/
total eIF2a) ratio calculated. All measures are displayed as percentage of no virus vehicle control. Note that levels of APP, BACE1 and p-eIF2a were
significantly elevated by either Ab42 oligomer treatment or GADD34 cont-AAV transduction alone, compared to no virus vehicle control. Similarly,
GADD34 CA-AAV transduction alone also elevated APP and BACE1 levels but completely abrogated eIF2a phosphorylation. Interestingly, GADD34
cont-AAV transduction plus Ab42 treatment increased APP and BACE1 levels and phospho/total eIF2a ratio to even greater extents than either
treatment alone. GADD34 CA-AAV transduction plus Ab42 treatment also elevated APP and BACE1 levels significantly, despite reducing the phospho/
total eIF2a ratio to only ,7% of no virus vehicle control. Bars represent SEM, n = 3 samples per condition, asterisks (*) indicate significant changes
compared to ‘‘vehicle no virus’’, p,0.05*, p,0.01**, p,0.001***.
doi:10.1371/journal.pone.0101643.g003
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Furthermore, reduction of eIF2a phosphorylation decreases
neither Ab42 level nor amyloid plaque pathology in vivo.
eIF2a S51A knockin mutation inhibits eIF2a
phosphorylation but does not reduce BACE1 elevation in
5XFAD transgenic mouse brain
Our AAV results suggested that brain injection of viral vectors
in general did not appear to affect the outcome of our
experiments. However, to provide further confidence and
additional support for our conclusions, we sought to reduce eIF2a
phosphorylation by a different genetic method that did not involve
virus injection. To do so, we crossed 5XFAD mice with
heterozygous eIF2a S51A knockin mice to generate 5XFAD;
eIF2a S/A bigenic offspring that have ,50% reduction of eIF2a
phosphorylation (5XFAD; S/A mice). Only S/A heterozygotes
could be analyzed, since A/A homozygotes die shortly after birth,
as reported previously [49]. Immunoblot analysis showed the
expected increase in BACE1 level for 12 month old 5XFAD; S/S
(wild-type) compared to non-Tg; S/S mice (Fig. 8). Importantly,
we oberved that BACE1 level in 5XFAD; S/A brain was the same
as that in 5XFAD; S/S brain, despite the fact that p:t eIF2a ratio
was reduced by over 40%. Additionally, Ab42 levels by ELISA
were unchanged between 5XFAD; S/A and 5XFAD; S/S
genotypes (data not shown). Once again, we could discern no
Figure 4. In primary neurons, genetic reduction of eIF2a phosphorylation via eIF2a S51A knockin mutation does not inhibit BACE1
and APP elevation in response to Ab42 oligomer treatment. Mixed cortical primary neurons were isolated from e15.5 mouse embryos that
were either homozygous for the eIF2a S51A targeted replacement mutation (A/A) or heterozygous (S/A). After 7 days in culture, neurons were
treated with vehicle or 10 mM Ab42 oligomers, lysed 30 hours later, and 10 mg/lane of protein were subjected to immunoblot analysis for APP, BACE1,
total eIF2a, phosphorylated (p)-eIF2a, and b-actin as a loading control. APP and BACE1 immunosignal intensities were normalized to those of b-actin.
Phosphorylated and total eIF2a immunosignal intensities were measured and phosphorylated:total eIF2a (phospho/total eIF2a) ratio calculated. All
measures are displayed as percentage of S/A vehicle control. As expected, levels of APP, BACE1, and p-eIF2a were significantly elevated by Ab42
oligomer treatment in S/A neurons, compared to vehicle. Importantly, Ab42 oligomers caused robust increases of BACE1 and APP levels in A/A
neurons, despite complete abrogation of eIF2a phosphorylation. There was no significant difference in BACE1 or APP levels in A/A compared to S/A
neurons, eliminating the problem that AAV treatment of primary neurons increases levels of BACE1, APP, and p-eIF2a. The small phospho/total eIF2a
ratio in vehicle treated A/A neurons is due to immunoblot background. Bars represent SEM, n = 6 samples per condition, asterisks (*) indicate
significant changes compared to S/A vehicle, p,0.05*, p,0.01**.
doi:10.1371/journal.pone.0101643.g004
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significant effect of the 5XFAD transgene on the p:t p-eIF2a ratio
compared to non-Tg mice, contrary to our previous report [22].
These results are consistent with those of our AAV experiments,
and provide further support for the conclusion that eIF2a
phosphorylation does not mediate amyloid-associated BACE1
elevation in the brain.
BACE1-YFP expressed from a transgene lacking the
BACE1 mRNA 59 UTR is also elevated and accumulates
around amyloid plaques in 5XFAD brain
Phosphorylated eIF2a increases BACE1 translation by causing
ribosome scan-through of three upstream open reading frames
Figure 5. BACE1 is elevated in 5XFAD transgenic mouse brain, with highest concentrations surrounding amyloid plaques. (A)
Hemibrains from 6 month old 5XFAD (+) mice (n = 17), and non-transgenic (Tg) (–) age-matched controls (n = 13) were homogenized and 20 mg/lane
of protein were subjected to immunoblot analysis for transgenic human (h) APP, BACE1, Ab, and bIII-tubulin as a loading control. (B) hAPP and BACE1
immunosignal intensities were normalized to those of bIII-tubulin and displayed as percentage of non-Tg control. Note that 5XFAD mice have
significantly elevated levels of BACE1 and Ab compared to non-Tg controls, as detected by BACE1 antibody clone 3D5 and human APP/Ab antibody
clone 6E10, respectively. Bars represent SEM, asterisks (*) indicate significant changes compared to non-Tg control, p,0.001***, (C) Coronal brain
sections from 5XFAD mice were co-stained with anti-BACE1 antibody (red) and Thioflavin S (green) for fibrillar amyloid and imaged by fluorescence
microscopy. At low magnification, high levels of BACE1 (red) are readily observed in mossy fibers of the hippocampus, which is the normal
localization pattern of BACE1 in the brain (BACE1, first row). At high magnification, BACE1 (red) is shown to concentrate abnormally in an annulus that
immediately surrounds the fibrillar amyloid plaque core (green; cortex, second row; hippocampus, third row). Scale bars = 1 mm, first row; 100 mm,
second and third rows.
doi:10.1371/journal.pone.0101643.g005
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Figure 6. Two-vector AAV system effectively transduces mouse brain, and GADD34 control AAV transduction does not elevate
levels of BACE1 or phosphorylated eIF2a in the brain. 5XFAD or non-Tg pups were injected on postnatal day 0 into lateral ventricles with 2 ml
per hemisphere containing 6.661010 viral genomes of GADD34 CA-AAV or GADD 34 cont–AAV plus 6.961010 viral genomes of CaMKII tTA-AAV. Mice
were aged to 6 months and brains harvested for immunoblot, and immunofluorescence microscopy analysis. (A) GFP fluorescence in coronal brain
sections of 6 month-old 5XFAD mice injected with GADD 34 cont–AAV (left column) or GADD34 CA-AAV (right column) shows comparable
expression levels of GFP from both transduced AAV vectors. Upper row: entire hemibrain sections showing wide-spread GFP expression, especially in
the hippocampus. Lower row: lower exposure of hippocampus showing cellular GFP expression. The AAV serotype 1 with the CaMKII promoter
effectively drives expression in excitatory forebrain neurons, with particularly high expression in the hippocampus. Scale bar = 1 mm (top row),
250 mm (bottom row). (B) Low exposure high magnification image of a section of the hippocampus from a mouse transduced with GADD34 CA-AAV
stained with an antibody against GADD34 (red) shows high co-localization of GADD34 CA and GFP in neurons of the CA regions, indicating that GFP
fluorescence is an effective proxy marker for GADD34 expression Scale bar = 250 mm. (C) 20 mg/lane of cortex or hippocampus homogenate from 6
month-old 5XFAD (+) and non-Tg (–) mice either uninjected (uninj) or GADD 34 cont–AAV injected (cont inj) were subjected to immunoblot analysis
for BACE1, total eIF2a, phosphorylated (p)-eIF2a, and bIII-tubulin as a loading control. All samples were transferred onto a single piece of PVDF
membrane, as described in Methods, and representative blots are shown here. (D) BACE1 immunosignal intensities were normalized to those of bIII-
tubulin. Phosphorylated and total eIF2a immunosignal intensities were measured and phosphorylated:total eIF2a (phospho/total eIF2a) ratio
calculated. All measures are displayed as percentage of uninjected non-Tg control. Comparison of GADD34 cont–AAV injected mice with genotype-
matched uninjected mice shows that there is no effect on BACE1 or p-eIF2a levels from AAV brain injection itself. n = 9–15 mice per group. Bars
represent SEM. Asterisks (*) indicate significant difference from non-Tg uninj p,0.01**, p,0.001***.
doi:10.1371/journal.pone.0101643.g006
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(uORFs) present in the 59 UTR of BACE1 mRNA [46], thus
increasing the probabilty of ribosome translation re-initiation at
the true BACE1 ORF [22]. A BACE1 transgene with a truncated
59 UTR lacking the uORFs does not result in increased BACE1
translation in response to energy deprivation stress that induces
eIF2a phosphorylation [22]. If Ab is also a stress that causes eIF2a
phosphorylation and increased BACE1 mRNA translation, we
reasoned that BACE1-YFP transgenic mice that express a
Figure 7. GADD34 CA-AAV effectively inhibits eIF2a phosphorylation in 5XFAD brain but does not block amyloid-associated
BACE1 elevation. 5XFAD or non-Tg pups were injected on postnatal day 0 into lateral ventricles with 2 ml per hemisphere of 6.661010 viral
genomes of GADD34 CA-AAV or GADD 34 cont–AAV plus 6.961010 viral genomes of CaMKII tTA-AAV. Mice were aged to 6 months and brains
harvested for immunoblot and immunofluorescence microscopy analysis. (A) 20 mg/lane of cortex or hippocampus homogenate from 6 month-old
5XFAD (+) and non-Tg (–) mice either GADD34 CA-AAV injected (CA) or GADD 34 cont–AAV injected (cont) were subjected to immunoblot analysis
for BACE1, total eIF2a, phosphorylated (p)-eIF2a, and bIII-tubulin as a loading control. All samples were transferred onto a single piece of PVDF
membrane, as described in Methods, and representative blots are shown here. (B) BACE1 immunosignal intensities were normalized to those of bIII-
tubulin. Phosphorylated and total eIF2a immunosignal intensities were measured and phosphorylated:total eIF2a (phospho/total eIF2a) ratio
calculated. All measures are displayed as percentage of GADD 34 cont–AAV injected non-Tg control. BACE1 levels were elevated in GADD 34 cont–
AAV transduced 5XFAD cortex and hippocampus compared to non-Tg, as expected. Importantly, GADD34 CA-AAV transduction reduced p-eIF2a
levels by ,85–90% compared to GADD34 cont-AAV transduction in both 5XFAD and non-Tg cortex and hippocampus. Despite this dramatic
inhibition of eIF2a phosphorylation, BACE1 levels were elevated in GADD34 CA-AAV transduced 5XFAD cortex and hippocampus to the same extent
as in GADD34 cont-AAV transduced 5XFAD cortex and hippocampus. n = 6–15 mice per group, bars represent SEM, asterisks (*) indicate significant
changes compared to non-Tg GADD34 cont-AAV control, NS = not significant, p,0.05*, p,0.01**, p,0.001***, (#) represents significant difference
between 5XFAD GADD34 cont-AAV and 5XFAD GADD34 CA-AAV p,0.001 ###. (C) Cortical homogenates from 5XFAD mice injected with either
GADD 34 cont–AAV or GADD34 CA-AAV were prepared for measurement of total (soluble plus insoluble) Ab42 levels (ng/mg total protein) by ELISA
(Methods). No significant difference in total Ab42 level between GADD34 CA-AAV and GADD34 cont-AAV brain transduction was observed. Bars
represent SEM (D) Coronal brain sections of representative GADD34 CA-AAV or GADD34 cont-AAV transduced 5XFAD mice co-stained with anti-
BACE1 antibody (green) and thiazine red (ThR) for fibrillar amyloid, then imaged by fluorescence microscopy. Both the intensities of BACE1
immunostaining and fibrillar plaque load signal appear unaffected by reduction of eIF2a phosphorylation via GADD34 CA-AAV transduction, thus
corroborating our immunoblot analysis that phosphorylated eIF2a does not mediate amyloid-associated BACE1 elevation. Each image is taken at 10x
objective magnification, at the same exposure, from the cortex just above hippocampal region CA3. Scale bar = 100 mm.
doi:10.1371/journal.pone.0101643.g007
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transcript with a truncated BACE1 mRNA 59 UTR under the
control of the CaMKII promoter [52] should not exhibit increased
BACE1-YFP levels associated with amyloid. Sequencing demon-
strated that only 11 nucleotides of the BACE1 mRNA 59 UTR
and no uORFs are present in the BACE1-YFP transgene 59 UTR
(Fig. 9A). To determine whether or not BACE1-YFP levels are
elevated in response to amyloid, we crossed BACE1-YFP
transgenics with 5XFAD mice to generate BACE1-YFP; 5XFAD
compound transgenic animals, aged them to 6–8 months, and
harvested cortices and hemibrains for biochemical and histological
analyses. Immunoblot analysis with an anti-BACE1 antibody
revealed that BACE1-YFP levels were significantly increased in
BACE1-YFP; 5XFAD brain homogenates, as compared to those
from age-matched mice that express BACE1-YFP alone (Fig. 9B).
Moreover, YFP fluorescence in brain sections from BACE1-YFP;
5XFAD mice demonstrated marked accumulation of BACE1-YFP
in swollen dystrophic neurites surrounding amyloid deposits in a
pattern identical to endogenous BACE1 immunostaining near
plaques in APP transgenic and AD brains (Fig. 5C; [24,26]). Thus,
BACE1-YFP underwent Ab-dependent elevation in 5XFAD
brain, even when expressed from a transgene lacking the 59
UTR uORFs that are directly responsible for the translational
control of BACE1 mRNA by phosphorylated eIF2a. Together
with our other genetic evidence, our BACE1-YFP transgenic
results strongly support the conclusion that amyloid-associated
BACE1 elevation occurs via a mechanism that is independent of
eIF2a phosphorylation.
Discussion
In this report we use three different genetic strategies (GADD34
CA-AAV transduction, eIF2a S51A knockin mutation, BACE1-
YFP transgene lacking 59UTR uORFs) to investigate the potential
role of eIF2a phosphorylation in Ab-dependent BACE1 elevation
in primary neuron culture and in the brain of the 5XFAD mouse
model of aggressive amyloid pathology. We unequivocally
demonstrate that partial or complete reduction of eIF2a
phosphorylation does not inhibit the Ab-associated increase of
BACE1 level either in vitro or in vivo. Furthermore, we show that
YFP-tagged BACE1, expressed from a transgene with a truncated
BACE1 mRNA 59 UTR lacking uORFs required for p-eIF2a
mediated translational control, is elevated and accumulates
around plaques in a pattern identical to endogenous BACE1 in
5XFAD brain. Additionally, p-eIF2a reduction did not block Ab-
dependent APP elevation in primary neurons, nor did it decrease
Ab levels or amyloid plaque pathology in 5XFAD brain. Thus, we
can conclude that eIF2a phosphorylation does not have a role in
Ab-associated BACE1 and APP elevation, or in amyloid
pathology, at least in primary neurons and 5XFAD mice.
Our three distinct genetic strategies produced results that were
very consistent with one another, making it highly unlikely that the
data were artifacts of the approaches. Taken together, they
strongly support the conclusion that amyloid-associated BACE1
elevation does not depend on eIF2a phosphorylation or on any
other translational or transcriptional mechanism. Instead, we
currently favor a hypothesis of Ab-dependent BACE1 elevation
that is driven at the post-translational level by dysregulation of
BACE1 localization and/or turnover. Future investigations will
shed light on the elusive mechanism of BACE1 elevation in AD.
It is notable that both BACE1 and APP levels became elevated
in primary neurons following exposure to Ab42 oligomers,
suggesting a feed-forward mechanism that establishes a vicious
pathogenic cycle of Ab generation. Here, we did not determine
whether APP increased in parallel with BACE1 in the brains of
5XFAD mice. However, we recently demonstrated the accumu-
lation of both BACE1 and APP in dystrophic axons surrounding
amyloid plaques in 5XFAD brains [24]. Previous studies suggest
that a halo of Ab oligomers is present around the amyloid plaque
[3], implying that neuritic dystrophy in close proximity to the
plaque might arise from Ab oligomer-induced toxicity. Putting
these observations together, we speculate that high concentration
Figure 8. Genetic reduction of eIF2a phosphorylation via eIF2a
S51A knockin mutation does not block amyloid-associated
BACE1 elevation in 5XFAD brain. 5XFAD mice were crossed with
mice harboring the eIF2a S51A targeted replacement mutation to
generate 5XFAD (+) or non-Tg (–) offspring that were either
heterozygous for the eIF2a S51A knockin mutation (S/A) or wild-type
(S/S). Mice were aged to 12 months, brains harvested, and homoge-
nates prepared. 20 mg/lane of brain homogenate were subjected to
immunoblot analysis for transgenic human (h) APP, BACE1, total eIF2a,
and phosphorylated (p)-eIF2a. All samples were transferred onto a
single piece of PVDF membrane and stained with ponceau S as a
protein loading control, as described in Methods. For quantification,
BACE1 immunosignal intensity was normalized to ponceau S staining
intensity for a given lane. Phosphorylated and total eIF2a immunosignal
intensities were measured and phosphorylated:total eIF2a (phospho/
total eIF2a) ratio calculated for a given lane. The means of each group
were calculated and means displayed as percentage of the mean non-
Tg S/S control. Both non-Tg and 5XFAD mice that were also
heterozygous for the eIF2a S51A knockin mutation had a ,40%
reduction in phospho/total eIF2a ratio compared to their S/S
counterparts; presumably, the phospho/total eIF2a ratios did not reach
the expected 50% reduction because of a high non-specific background
on the p-eIF2a immunoblot or partial compensatory increased
phosphorylation of the wild type allele. Importantly, BACE1 level in
5XFAD; S/A brain showed an amyloid-associated elevation that was
equivalent to that of 5XFAD; S/S brain, despite the 40% reduction in
phospho/total eIF2a ratio. n = 19–30 mice per group. Bars represent
SEM, asterisks (*) indicate significant changes compared to non-Tg S/S
control, p,0.05*, p,0.01**, p,0.001***, NS = not significant, (#)
indicates significant difference between 5XFAD S/S and 5XFAD S/A p,
0.001 ###.
doi:10.1371/journal.pone.0101643.g008
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Figure 9. BACE1-YFP expressed from a transgene with a truncated BACE1 mRNA 59 UTR is also elevated and accumulates around
amyloid plaques in 5XFAD brain. (A) 59 UTR of BACE1-YFP transgene. The BACE1-YFP coding region (green) was subcloned into the tetO
promoter vector PMM400 (black) via an NheI site (gray) [52], leaving a severely truncated BACE1 mRNA 59 UTR (orange) consisting of only eleven
nucleotides that lack the uORFs required for de-repression of translation by phosphorylated eIF2a. (B) 5XFAD mice were crossed with BACE1-YFP
transgenic mice to generate 5XFAD (+) and non-Tg (–) offspring that also expressed the BACE1-YFP transgene. 5XFAD and non-Tg offspring that
lacked the BACE1-YFP transgene were also generated. At 6–8 months of age, cortices of 5XFAD; BACE1-YFP, non-Tg; BACE1-YFP, 5XFAD, and non-Tg
littermates (n = 5 for each group) were harvested, homogenized, and 20 mg/lane of homogenates were subjected to immunoblot analysis for BACE1
using the 3D5 anti-BACE1 antibody. The immunoblot was stained with ponceau S as a protein loading control. Representative BACE1-YFP
immunoblot signals are shown. BACE1-YFP runs at ,90 kDa on SDS-PAGE, compared to ,65 kDa for endogenous (endog.) BACE1. For
quantification, BACE1 and BACE1-YFP immunosignal intensities were normalized to ponceau S staining intensity for a given lane. The means of each
group were calculated and means displayed as percentage of the mean BACE1 level in non-Tg control. The BACE1-YFP transgene is expressed at
levels that are ,4-fold higher than that of endogenous BACE1. As expected, endogenous BACE1 level is significantly elevated in 5XFAD brain
compared to non-Tg brain. Most importantly, BACE1-YFP levels also exhibit a significant amyloid-associated elevation with the 5XFAD genotype
compared to the non-Tg genotype, despite the complete absence of uORFs necessary for regulation by eIF2a phosphorylation. Bars represent SEM,
asterisks (*) indicate significant changes compared to respective non-Tg control, p,0.05*. (C) Sagittal section of representative 5XFAD; BACE1-YFP
cortex stained with anti-BACE1 antibody and imaged for BACE1 immunofluorescence (red) and YFP fluorescence (green) by confocal microscopy.
Upper row shows lower magnification of several amyloid plaques (stars) each surrounded by an annulus of punctate accumulations of BACE1 and
BACE1-YFP. Lower row shows higher magnification image of boxed inset in upper row. Our previous work has identified these BACE1 accumulations
as swollen dystrophic axons and presynaptic terminals [24]. Note the extensive co-localization of BACE1 and BACE1-YFP, although their relative levels
appear to vary somewhat in different dystrophies. These results demonstrate that BACE1-YFP accumulates around plaques in the same pattern as
endogenous BACE1. Blue in the center of the annulus represents the amyloid plaque core, marked with (*). Blue outside of the annulus indicates
DAPI-stained nuclei.
doi:10.1371/journal.pone.0101643.g009
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Ab42 oligomers emanating from plaques cause peri-plaque
neurites to become swollen and dystrophic, leading to the
accumulation of BACE1 and APP with subsequent elevated Ab
production.
Our results differ from others suggesting a role for eIF2a
phosphorylation in amyloid-associated elevation of BACE1 levels
and amyloid pathology. BACE1 and p-eIF2a levels have been
reported to increase together under certain genetic and pharma-
cologic conditions in APP transgenic mice [22,69–71]. However,
these observations are essentially correlative and the correspond-
ing studies did not test the effects of direct inhibition of eIF2a
phosphorylation on Ab-induced BACE1 levels, as did our present
investigation. For example, in one study 5XFAD mice were
generated that lacked the eIF2a kinase GCN4 [70]. 5XFAD;
GCN42/2 mice exhibited elevated p-eIF2a, BACE1, and Ab
levels compared to 5XFAD; GCN4+/+ littermates. A compensa-
tory increase in the activation of another eIF2a kinase, PERK, was
also observed in 5XFAD; GCN42/2 mice, providing an
explanation for the p-eIF2a elevation. However, this study did
not directly demonstrate that the BACE1 elevation was caused by
the increase in p-eIF2a. Indeed, levels of proteins important for
the regulation of gene expression such as ATF4 and phosphor-
ylated CREB were also changed in 5XFAD; GCN42/2 mice,
suggesting the possibility of alternative pathways of BACE1
elevation independent of p-eIF2a. The other reports also suffer
from over-interpretation of correlative results. In support of our
results, a recent study using a different APP transgenic mouse
reported that genetic ablation of PERK reduced p-eIF2a levels but
did not alter BACE1 levels [72]. By direct inhibition of eIF2a
phosphorylation, here we definitively tested cause and effect
relationships and conclusively show that reducing eIF2a phos-
phorylation does not decrease amyloid-associated BACE1 eleva-
tion in primary neuron cultures or 5XFAD mice.
We note that there are conflicting reports concerning the level
of p-eIF2a present in the brains of 5XFAD mice. We previously
reported that the p:t eIF2a ratio in 5XFAD mice at 6 months of
age was increased modestly (,20%) compared to non-Tg mice
[22]. However, we failed to confirm this finding in the present
study and instead showed no significant difference in p:t eIF2a
ratio between 6- or 12-month 5XFAD and non-Tg mice using a
much larger sample size (n = 9–15 here compared to n= 5 in [22]).
Another group has reported that p-eIF2a levels are increased ,3-
and ,9-fold at 6 and 15–18 months of age, respectively [69]. The
reason for these discrepancies in reported p-eIF2a levels in
5XFAD mice is unclear and will require further investigation to
resolve. However, it is worth noting that 2–12 month-old 5XFAD
mice display robust increases in BACE1 levels despite failing to
show consistently elevated p-eIF2a in our hands, again arguing
against a definitive role for eIF2a phosphorylation in amyloid-
associated BACE1 elevation.
On a technical note, this study demonstrates the effective use of
a two-vector AAV system with P0 intracerebroventricular
injection for transgene expression in the brain. Previous studies
using this injection method have used a single virus, which limits
the flexibility of the regulation of the transduced transgene. AAV
vectors can package only a limited sized cDNA insert (,5–6 kb)
between the inverted terminal repeats, so our demonstration of the
feasibility of AAV co-transduction expands the possibility for more
complex regulation and combinations of different transgenes. In
our study, AAV co-transduction permitted us to double the
amount of exogenous DNA (e.g., for co-expression of the gene of
interest with GFP) and perform cell specific expression in neurons
coupled with doxycycline regulation (which we did not use in this
study).
Our two-vector system requires that individual cells become
infected with a sufficient number of each AAV to achieve adequate
expression of both vectors. Since we were able to almost
completely eliminate eIF2a phosphorylation, it appears that
sufficient co-infection levels of GADD34 CA-AAV and CamKII
tTA-AAV vectors were attained at the non-toxic titers that we
used (see Methods). It is notable that eIF2a phosphorylation was
reduced by as much as 90%, suggesting that the majority of p-
eIF2a in the brain is found in excitatory forebrain neurons (in
which CaMKII tTA-AAV is specifically expressed) rather than in
other cell types.
Our recent work here and in another report [25] focused on
whether dysregulation of specific cellular mechanisms that control
BACE1 levels in neurons is responsible for Ab-dependent BACE1
elevation. Taken together, our data suggest that while pathways
involving eIF2a phosphorylation, Cdk5 activity and Caspase 3
activation, among others have a role in regulating BACE1 levels
under normal physiological conditions and stress responses, these
mechanisms are not responsible for raising BACE1 levels in an
Ab42 dependent fashion. Clearly, BACE1 translation can be
upregulated by different stresses that induce eIF2a phosphoryla-
tion, such as energy deprivation [22], and this mechanism is
undoubtedly important during certain stress responses. While our
work suggests it is highly unlikely that eIF2a phosphorylation is
responsible for increased BACE1 levels observed in Ab42 treated
primary neurons or 5XFAD brains, further investigation of this
pathway is still relevant as p-eIF2a levels are elevated in the brains
of AD patients [22] and could affect AD pathology through
mechanisms other than BACE1 elevation.
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